TriSalus Life Sciences Inc (NASDAQ:TLSI) Reports Q3 2025 Results with Strong Revenue Growth but Significant EPS Miss

TriSalus Life Sciences Inc (NASDAQ:TLSI) has released its financial results for the third quarter of 2025, presenting a mixed financial picture characterized by strong revenue growth but a significant earnings miss relative to analyst expectations. The market's immediate reaction appears to reflect this dichotomy, with the stock trading lower in after-hours activity.

Earnings and Revenue Performance Versus Estimates

The company's top-line performance demonstrated considerable strength during the quarter, while bottom-line results fell substantially short of Wall Street forecasts.

• Revenue: $11.57 million, representing a 57% increase year-over-year and slightly exceeding analyst estimates of $11.99 million.
• Earnings Per Share (EPS): Reported a loss of $0.96 per share, which was significantly wider than the estimated loss of $0.15 per share.

This divergence between revenue outperformance and a substantial EPS miss appears to be the primary driver behind the negative after-market price movement. Investors are likely weighing the robust sales growth against the deeper-than-expected loss.

Operational Highlights and Business Update

Beyond the headline financial figures, TriSalus provided several key operational updates that illustrate the company's strategic direction. The quarter was marked by significant commercial progress and a strategic refinement of the company's development pipeline.

The performance of the TriNav® Infusion System remains the core driver of current business, with the company reporting expanding clinical adoption for liver-directed therapies. Management reaffirmed its full-year 2025 revenue growth guidance of 50%, signaling confidence in the continued commercial trajectory. Operationally, the company highlighted a reduction in its quarterly cash burn by approximately 50% compared to the previous quarter, a positive development for its financial sustainability.

A notable strategic shift was the decision to seek partnership opportunities for the development of nelitolimod, the company's investigational immunotherapeutic. This move is intended to reduce development costs and allow the company to focus resources on its commercial platform and other pipeline applications for its PEDD® technology. The company also completed an exchange offering for its Series A Preferred stock, simplifying its capital structure.

Financial Health and Liquidity

From a balance sheet perspective, TriSalus reported cash and cash equivalents of $22.7 million as of September 30, 2025. The company stated this provides sufficient runway to reach positive adjusted EBITDA, a key non-GAAP profitability metric which showed improvement, with losses narrowing to $5.4 million from $7.2 million in the prior year period.

Forward Outlook and Analyst Expectations

Looking ahead, the market will be watching to see if the company's reaffirmed 50% full-year revenue growth guidance can be met. For the next quarter (Q4 2025), analysts are currently estimating revenue of $13.37 million and an EPS loss of $0.10. The company's ability to meet or exceed these forthcoming estimates, while continuing to manage its operational expenses, will be critical for investor sentiment.

For a detailed look at historical earnings and future analyst estimates for TriSalus Life Sciences, you can review the data here.

---

Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. The information presented is based on publicly available data and should not be relied upon as the sole basis for making an investment decision. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.